Unknown

Dataset Information

A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19.


ABSTRACT:

Background

The outbreak of a new coronavirus (SARS-CoV-2) poses a great challenge to global public health. New and effective intervention strategies are urgently needed to combat the disease.

Methods

We conducted an open-label, non-randomized, clinical trial involving moderate COVID-19 patients according to study protocol. Patients were assigned in a 1:2 ratio to receive either aerosol inhalation treatment with IFN-κ and TFF2, every 48 h for three consecutive dosages, in addition to standard treatment (experimental group), or standard treatment alone (control group). The end point was the time to discharge from the hospital. This study is registered with chictr.org.cn, ChiCTR2000030262.

Findings

A total of thirty-three eligible COVID-19 patients were enrolled from Feb

SUBMITTER: Fu W 

PROVIDER: S-EPMC7388798 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature